61 results about "Hedgehog signaling pathway" patented technology

The present invention provides combination therapy methods of treating a proliferative disease (such as cancer) comprising administering to an individual an effective amount of a taxane in a nanoparticle composition, and a hedgehog inhibitor that inhibits a hedgehog signaling pathway.

The present invention makes available methods and reagents for inducing activation of a hedgehog pathway in a cell or tissue comprising contacting the cell with a hedgehog agonist, such as a small molecule, in a sufficient amount to achieve a therapeutic result. In certain embodiments, the methods and reagents may be employed to correct or inhibit an aberrant or unwanted growth state, e.g., by antagonizing a normal ptc pathway or agonizing smoothened or hedgehog activity.

The present invention makes available methods and reagents for inhibiting aberrant growth states resulting from hedgehog gain-of-function, ptc loss-of-function or smoothened gain-of-function comprising contacting the cell with a hedgehog antagonist, such as a small molecule, in a sufficient amount to aberrant growth state, e.g., to agonize a normal ptc pathway or antagonize smoothened or hedgehog activity.

The invention provides a method, compounds and compositions for modulating the activity of the hedgehog signaling pathway. In particular, the invention provides a method for inhibiting aberrant growth states resulting from phenotypes such as Ptc loss-of-function, hedgehog gain-of-function, smoothened gain-of-function or GIi gain-of-function, comprising contacting a cell with a sufficient amount of a compound of Formula (I).

The present invention makes available methods and reagents for inhibiting aberrant growth states resulting from hedgehog gain-of-function, ptc loss-of-function or smoothened gain-of-function comprising contacting the cell with a hedgehog antagonist, such as a small molecule, in a sufficient amount to aberrant growth state, e.g.,to agonize a normal ptc pathway or antagonize smoothened or hedgehog activity.

The present invention relates to a DYRK1B inhibitor for use in the treatment of cancer, wherein in said cancer and/or in cells of said cancer the hedgehog signaling pathway is activated, and in particular the activation of the hedgehog signaling pathway is independent of signaling by the G protein-coupled receptor Smoothened.

The invention provides methods for modulating, e.g., antagonizing, the activity of the Hedgehog signaling pathway, and for treating Hedgehog related disorders such as cancers (e.g., medulloblastoma). In particular, the invention provides methods for inhibiting aberrant growth states resulting from phenotypes such as Ptch loss-of-function, Hedgehog gain-of-function, smoothened gain-of-function or Gli gain-of-function by administering to a mammal combinations of Smoothened inhibitors (e.g., a compound of Formula I, Formula II, or Formula III, or any of the compounds listed herein or incorporated by reference) and cholesterol biosynthesis pathway inhibitors (e.g., statins), Gli inhibitors, and/or Phosphatidylinositol 3-kinase (PI3K) inhibitors.

The invention provides a method for modulating the activity of the hedgehog signaling pathway. In particular, the invention provides a method for inhibiting aberrant growth states resulting from phenotypes such as Ptc loss-of-function, hedgehog gain-of-function, smoothened gain-of-function or Gli gain-of-function, comprising contacting a cell with a sufficient amount of a compound of Formula I.

The invention discloses a hedgehog signal pathway gene associated with amputated limb regeneration of Periplaneta americana and application of dsRNA thereof. The results showed that Hh gene, Ptc gene,Smo gene and/or Ci gene had the ability to affect the limb regeneration of Periplaneta americana. Moreover, silencing the expression of Hh, Ptc, Smo and Ci genes could inhibit the regeneration ability of Periplaneta americana, which could not only remove the pests of Periplaneta americana efficiently, but also avoid the environmental pollution and is safe and reliable. Hh, Ptc, Smo and Ci gene ofthat invention can be used as control target of Periplaneta americana pest control.

The invention provides a method for modulating the activity of the hedgehog signaling pathway. In particular, the invention provides a method for inhibiting aberrant growth states resulting from phenotypes such as Ptc loss-of-function, hedgehog gain-of-function, smoothened gain-of-function or Gli gain-of-function, comprising contacting a cell with a sufficient amount of a compound of Formula I.

The invention provides an androstane derivative, a preparation method and applications thereof, and belongs to the technical field of medicine. According to the present invention, the androstane derivative has good inhibitory effect on Hedgehog signaling pathway so as to provide an effective treatment drug for patients with chronic myelogenous leukemia; the results of the embodiments show that the androstane derivative has the Hedgehog pathway signaling inhibition average IC50 value measured by using mouse [s12] and human [MZ24] Gli reporter cell lines of 0.020 [mu]m while the average IC50 value of the existing FDA-approved Hedgehog pathway inhibitor is 0.022 [mu]M, such that the androstane derivative has Hedgehog signaling pathway inhibition effect, and further achieve the effect comparable to Vismodegib.

The present invention provides jervine or its pharmaceutically acceptable salt thereof as an active ingredient of antitumor drugs. This invention proves jervine strongly inhibits the hedgehog signal pathway and effectively inhibits the tumor growth using three human tumor xenograft models including lung cancer, pancreatic cancer and basal cell carcinoma in nude mice. Jervine has the potential to be a new antitumor agent.

The invention belongs to the field of medicine technology, and relates to an anti-tumor pharmaceutical composition targeting hedgehog pathway and autophagy. The drug has a significant synergistic effect in the treatment of solid tumors and non-solid tumors, especially has a very significant anti-tumor effect on drug-resistant chronic myelogenous leukemia. The pharmaceutical composition disclosed by the invention has extensive antitumor activity and has good clinical application prospect.